

## CURRENT CRU PROJECTS

IRBNET #	PRINCIPAL INVESTIGATOR	PROTOCOL DESCRIPTION	SPONSORS	RESEARCH TEAM Contact
<b>DEPARTMENT OF OB/GYN</b>				
<b>365887</b>	Mary Cunningham, MD	GOG 225: Lifestyle Intervention for Ovarian Cancer Enhanced Survival (LIVES)	Gynecologic Oncology Group	Jennifer Moore, CCRP <b>315-470-2620</b>
<b>762422</b>	Mary Cunningham, MD	GOG 3005: A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Gynecologic Oncology Group	Jennifer Moore, CCRP <b>315-470-2620</b>
<b>1237861</b>	Mary Cunningham, MD	A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin /Bevacizumab in Platinum ReSISTANT Ovarian Cancer.	Gynecologic Oncology Group	Jennifer Moore, CCRP <b>315-470-2620</b>